SHR 6390Alternative Names: SHR 6390
Latest Information Update: 21 Apr 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant melanoma
Most Recent Events
- 19 Feb 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease) in China (NCT02684266)
- 01 Jan 2016 Phase-I clinical trials in Malignant melanoma (Late-stage disease, Inoperable/Unresectable) in China (PO) (NCT02671513)
- 30 Dec 2015 Preclinical trials in Malignant melanoma in China (PO)